BioXcel Therapeutics Initiates Pivotal Phase 3 Studies Of BXCL501 For Acute Treatment Of Agitation In Patients With Schizophrenia And Bipolar Disorder

BioXcel Therapeutics (“BTI” or “Company”) (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines

Benzinga · 12/30/2019 12:01

BioXcel Therapeutics (“BTI” or “Company”) (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced the initiation of its SERENITY (Sub-Lingual DExmedetomidine in Agitation Associated With SchizophRENIa and Bipolar Disorder STudY) program, two Phase 3 studies of BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. Topline data from both Phase 3 trials are expected in mid-2020.